G1 Therapeutics to Provide Second Quarter Corporate and Financial Update on August 7, 2019
31 July 2019 - 9:00PM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology
company, today announced that it will host a webcast and conference
call to provide a corporate and financial update for the second
quarter of 2019 on Wednesday, August 7, 2019 at 4:30 p.m. ET.
The live call may be accessed by dialing 866-763-6020 (domestic)
or 210-874-7713 (international) and entering the conference code:
7989125. A live and archived webcast will be available on the
Events & Presentations page of the company’s website:
www.g1therapeutics.com.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
clinical-stage biopharmaceutical company focused on the discovery,
development and delivery of innovative therapies that improve the
lives of those affected by cancer. The company is advancing three
clinical-stage programs. Trilaciclib is a first-in-class
myelopreservation agent designed to improve outcomes for patients
being treated with chemotherapy. Lerociclib is a differentiated
oral CDK4/6 inhibitor designed to enable more effective combination
treatment strategies. G1T48 is a potential best-in-class oral
selective estrogen receptor degrader (SERD) for the treatment of
ER+ breast cancer. G1 also has an active discovery program focused
on cyclin-dependent kinase targets.
G1 is based in Research Triangle Park, NC. For additional
information, please visit www.g1therapeutics.com and follow us on
Twitter @G1Therapeutics.
Contact:Jeff MacdonaldHead of
Investor Relations/Public
Relations919-907-1944jmacdonald@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Jul 2024 to Aug 2024
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Aug 2023 to Aug 2024